Diffuse Intrinsic Pontine Glioma (DIPG) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Diffuse Intrinsic Pontine Glioma (DIPG) Market Outlook

Thelansis’s “Diffuse Intrinsic Pontine Glioma (DIPG) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Diffuse Intrinsic Pontine Glioma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Diffuse Intrinsic Pontine Glioma (DIPG) Overview

Diffuse intrinsic pontine glioma (DIPG) is an aggressive form of childhood cancer primarily found in the brainstem, with a remarkably low occurrence rate that predominantly affects pediatric patients. Approximately 10% of DIPG cases lack specific histological features such as mitotic figures and microvascular proliferation, aligning them with WHO grade II tumors. The prevailing theory regarding DIPG development attributes it to a mutation in the H3 gene, specifically within the N-terminal tail of histone H3. Recent discoveries have revealed these mutations to be prevalent in midline pontine high-grade gliomas, especially in DIPG. The substitution of lysine at position 27 within the H3 encoding gene plays a pivotal role in driving DIPG's oncogenic process. It is suggested that any mutation targeting one of the histone H3 variants (H3.1, H3.2, or H3.3) may contribute to DIPG development. The H3K27 mutation and the loss of H3K27me3 are crucial markers, as they are characteristic of DIPG and likely represent the initial genomic event leading to tumor transformation. To diagnose suspected DIPG, the most effective diagnostic study involves magnetic resonance imaging (MRI) of the brain, both with and without contrast. Typically, over 50% of the enlarged ventral pons will exhibit an elevated signal on the T2 FLAIR MRI sequence. Treatment involves the administration of steroids, specifically dexamethasone, with the aim of stabilizing neurological symptoms until potential neurosurgical biopsy or radiation therapy becomes feasible. However, the prognosis for DIPG remains bleak due to the lack of effective therapies. It stands as the leading cause of death among childhood brain tumors, with most patients diagnosed before the age of seven. Following diagnosis, the median survival period is typically a mere nine months, and only a small minority, approximately 10%, manage to survive beyond two years. When compared to pediatric glioblastoma, DIPG's prognosis is the bleakest, with a significantly lower overall survival rate.

• DIPG has an incidence rate of 1 to 2 cases per 100,000 in the population, with a peak occurrence between the ages of 6 and 9, and a slightly higher prevalence among males. Brainstem gliomas afflict around 350 to 450 children annually in the United States, constituting the primary cause of death among children with brain tumors.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: